Ardia Announces Additional Positive Results On Gout Drug - Wall Street Journal

Ardia Announces Additional Positive Results On Gout Drug Wall Street Journal Ardia Biosciences Inc. (RDEA) announced additional positive interim results of its gout drug candidate at a conference in Rome. In the study of 123 gout ... Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate ...PR Newswire (press release) Ardea Biosciences Reveals Additional Positive Results From Phase 2 Trials For ...Daily Markets all 22 news articles »

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... - PR-inside.com (press release)

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... PR-inside.com (press release) ACZ885 significantly reduced rate of acute flares up to 75% vs. anti-inflammatory colchicine in gout patients starting uric acid lowering therapy (UALT)[1] ... Novartis ACZ885 prevented acute flares in gout patiends shows studyFrontier India - News, Analysis, Opinion EULAR: Novel Agent Eases Gout PainMedPage Today all 8 news articles »

Regeneron Sees Mixed Results on Gout Drug Trials - Wall Street Journal

Regeneron Sees Mixed Results on Gout Drug Trials Wall Street Journal Regeneron Pharmaceuticals Inc. reported Wednesday mixed results from Phase III trials of its gout drug Arcalyst, with one trial showing ... Regeneron gout drug works in one trial, fails otherReuters Regeneron gout drug meets study goalsBusinessWeek All About Gout: Arcalyst Meets Phase III Prophylaxis EndpointBioWorld Online Monthly Prescribing Reference -FierceBiotech -Daily Markets all 74 news articles »

Gout Patients Say The Condition Isn't Taken Seriously - RTT News

RTT News

Gout Patients Say The Condition Isn't Taken Seriously RTT News (RTTNews) - An earlier version of this story stated that Dr. Zorba Paster was the lead researcher on the gout study. The following article corrects to ... Gout sufferers call pain 'miserable'Dr. Cutler all 2 news articles »